Business Wire

Czech Technical-UPenn-NYU Team Wins Grand Challenge in US$5-Million MBZIRC2020 Organized by Khalifa University

26.2.2020 17:14:00 EET | Business Wire | Press release

Share

H.E. Dr. Mugheer Khamis Al Khaili, Member of the Executive Council, and Chairman of Department of Community Development today honored the Grand Challenge team winners Czech Technical University-University of Pennsylvania-NYU and winners of the three Challenge categories at the three-day US$5-million Mohamed Bin Zayed International Robotics Challenge (MBZIRC) 2020 that concluded in Abu Dhabi, organizers Khalifa University of Science and Technology announced today.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200226005539/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Czech Technical-UPenn-NYU Team Wins Grand Challenge in US$5-Million MBZIRC2020 organized by Khalifa University (Photo: AETOSWire)

The winning teams in all three categories – Challenge 1, 2, and 3 – also received awards from H.E. Dr. Mugheer Khamis Al Khaili at the ceremony.

His Excellency Hussein Bin Ibrahim Al Hammadi, Steering Committee General Chair, MBZIRC 2020, Dr. Arif Sultan Al Hammadi, Steering Committee General Co-Chair, and His Excellency Dr. Mohammed Al Mualla, Steering Committee Member, were present.

Others who attended the ceremony included UAE government officials, Challenge partners, stakeholders from the academia, research, and industry, as well as all the MBZIRC 2020 team members.

The Czech Technical University-University of Pennsylvania-NYU team won the first position in the Grand Challenge. The University of Bonn team came second, while the combined team of Universidad Politecnica Madrid-Universidad Pablo Olvide Poznan University of Technology- Centre National de la Recherche Scientifique won the third place.

The Beijing Institute of Technology topped Challenge 1 category with the Czech Technical University-University of Pennsylvania-NYU team and the University of Tokyo in the second and third places, respectively, while the Czech Technical University-University of Pennsylvania-NYU team won the Challenge 2 category with Nimbro (University of Bonn) and Technical University of Denmark in the second and third places. Challenge 3 was won by University of Seville-Tecnico Lisboa-CATEC team, while the Technical University of Denmark and the University of New South Wales-Sydney tied for the second place.

The 32 finalists, representing 17 countries, were shortlisted out of 134 teams from across the globe that applied to compete in MBZIRC 2020.

Dr. Arif Sultan Al Hammadi said: “The second edition of MBZIRC has emphatically placed MBZIRC as one of the most prestigious competitions in robotics and artificial intelligence globally, while positioning Khalifa University as the leading higher education institution driving innovation in all areas of science, engineering, and newly-emerging technologies.”

Dr. Al Hammadi added: “Congratulations to all the winners of MBZIRC 2020, especially the Grand Challenge winner and winners of all three Challenge categories. However, all the participating teams deserve credit for their commitment, determination and perseverance during the competition, consistently raising the bar of excellence as displayed by various autonomous drones. Through this Challenge, we have witnessed how technology continues to evolve and we firmly believe the advancements demonstrated by these UAVs and UGVs will very soon become part of our everyday lives.”

For more information, please visit: http://www.ku.ac.ae/

*Source: AETOSWire

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

APCO Worldwide
Abdullah Al Sayed, Account Director, +971504887044
aalsayed@apcoworldwide.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 12:48:00 EEST | Press release

Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye